other programs in development

Nanolipogel Formulations

yielding enhanced activity in established targets with co-delivery platform

Combination therapies are a potentially powerful approach to combating many forms of cancer, but effectiveness can vary when combination therapies are administered through separate delivery systems. PORT-4 (SAUG-1 and SAUG-2) aims to deliver combination cancer treatments in a single medicine.

The PORT-4 platform’s co-formulation approach creates the potential for delivering customized combinations of effective therapies that combine two separate drugs into a single medicine. Initial portfolio programs combine the delivery of approved PD-1 checkpoint inhibitors with the delivery of other drugs known to facilitate immune regulation, including cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) aptamer and vascular endothelial growth factor (VEGF) small molecules.

Initial programs for PORT-4 are currently undergoing preclinical testing.

STING agonist with VLP delivery

enabling convenient systemic administration and co-formulations with other agents

PORT-5 (STIM1) offers a first-in-class approach to developing molecules that activate the STING pathway, an immune-boosting pathway that has long been an area of interest in cancer treatment. PORT-5 packages a STING agonist, cGMP, in a virus-like particle (VLP), a delivery system that can be customized and targeted to specific cells and tumor types across the entire body. The resulting therapy can be administered systemically one or more targeted agents can be packaged within the VLP to increase its potency.

Data presented at the American Association for Cancer Research (AACR) 2022 conference showed that PORT-5 can be delivered systemically and achieve potent activation of the STING pathway preferentially in dendritic cells. The company is completing the IND enable work to allow entry into the clinic.